Background. Recent mathematical models have been developed to study the dynamics of chronic myelogenous leukemia (CML) under imatinib treatment. None of these models incorporates the anti-leukemia immune response. Recent experimental data show that imatinib treatment may promote the development of anti-leukemia immune responses as patients enter remission [1]. Methodology/Principal Findings. Using these experimental data we develop a mathematical model to gain insights into the dynamics and potential impact of the resulting anti-leukemia immune response on CML. We model the immune response using a system of delay differential equations, where the delay term accounts for the duration of cell division. The mathematical model suggests that ant...
We propose and analyze a system of partial differential equations (PDEs) for chronic myeloid leukemi...
Abstract Although imatinib is an effective treatment for chronic myelogenous leukemia (CML), and nea...
We describe a deterministic and a stochastic model to understand the dynamics of chronic myelogenous...
International audienceWe describe here a simple model for the interaction between leukemic cells and...
© 2005 Nature Publishing GroupThe clinical success of the ABL tyrosine kinase inhibitor imatinib in ...
Imatinib and other tyrosine kinase inhibitors (TKI) have improved treatment of chronic myelogenous l...
In this paper, we consider a system of nonlinear delay-differential equations (DDEs) which models th...
Chronic myelogenous leukemia (CML) is a cancer that begins in the bone marrow and spreads to the blo...
Chronic myelogenous leukemia (CML) is a cancer of the blood, and the im-mune system is known to play...
Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibito...
Recent clinical findings in chronic myeloid leukemia (CML) patients suggest that the risk of molecul...
Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibito...
International audienceThis paper focuses on the stability analysis of a delay-differential system en...
International audienceWe propose and analyze a simplified version of a partial differential equation...
Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed pa...
We propose and analyze a system of partial differential equations (PDEs) for chronic myeloid leukemi...
Abstract Although imatinib is an effective treatment for chronic myelogenous leukemia (CML), and nea...
We describe a deterministic and a stochastic model to understand the dynamics of chronic myelogenous...
International audienceWe describe here a simple model for the interaction between leukemic cells and...
© 2005 Nature Publishing GroupThe clinical success of the ABL tyrosine kinase inhibitor imatinib in ...
Imatinib and other tyrosine kinase inhibitors (TKI) have improved treatment of chronic myelogenous l...
In this paper, we consider a system of nonlinear delay-differential equations (DDEs) which models th...
Chronic myelogenous leukemia (CML) is a cancer that begins in the bone marrow and spreads to the blo...
Chronic myelogenous leukemia (CML) is a cancer of the blood, and the im-mune system is known to play...
Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibito...
Recent clinical findings in chronic myeloid leukemia (CML) patients suggest that the risk of molecul...
Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibito...
International audienceThis paper focuses on the stability analysis of a delay-differential system en...
International audienceWe propose and analyze a simplified version of a partial differential equation...
Treatment with the tyrosine kinase inhibitor imatinib is the standard of care for newly diagnosed pa...
We propose and analyze a system of partial differential equations (PDEs) for chronic myeloid leukemi...
Abstract Although imatinib is an effective treatment for chronic myelogenous leukemia (CML), and nea...
We describe a deterministic and a stochastic model to understand the dynamics of chronic myelogenous...